<DOC>
	<DOCNO>NCT01402817</DOCNO>
	<brief_summary>This pilot study determine adult child neurofibromatosis type 1 plexiform tumor give Sutent® respond drug therapy .</brief_summary>
	<brief_title>Study Sutent®/Sunitinib ( SU11248 ) Subjects With NF-1 Plexiform Neurofibromas</brief_title>
	<detailed_description>This open-label pilot study evaluate efficacy Sutent® individual NF1 clinically significant plexiform tumor . A secondary goal study seek improve current novel tool evaluate tumor response plexiform tumor . The rationale study arise response human murine NF1 cell Sutent® vitro clinical response individual NF1 use similar drug , Gleevec® . Following enrollment adult subject start receive Sutent® month 25mg day 28 day . Subjects 14 day without take Sutent® . If tolerate dose increase 37.5mg 50mg regimen ( 28 day take medication follow 14 without ) . Children start dose 10mg/m2/day day 28 day . They 14 day without take Sutent® . If tolerate dose increase 15mg/m2/day .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma , Plexiform</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Age : patient must ≥3 year age ≤65 year age time study entry 2 . Diagnosis : Patients must meet clinical diagnostic criterion neurofibromatosis type 1 ( NF1 ) . Patients must clinically significant plexiform neurofibroma ( biopsy proven possible tissue block available ) . Clinically significant tumor potentially life threaten impinge vital structure significantly impair quality life pain symptom . 3 . Disease status : Patients must measurable disease . 4 . Performance Level : Karnofsky ≥50 patient &gt; 10 year age Lansky ≥50 patient ≤10 year age . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . 5 . Prior therapy : Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study . 1 . Myelosuppressive chemotherapy : Must receive within 3 week entry onto study . 2 . Hematopoietic growth factor : At least 14 day since completion therapy growth factor . 3 . Biologic ( antineoplastic agent ) : At least 7 day since completion therapy biologic agent . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss principal investigator . 4 . XRT : ≥2 week local palliative XRT ( small port ) ; ≥6 month must elapse ≥50 % radiation pelvis ; ≥6 week must elapse substantial BM radiation . 6 . Organ function requirement . Adequate bone marrow function define . Peripheral absolute neutrophil count ( ANC ) ≥1000/µL ii . Platelet count ≥100,000/ µL ( transfusion independent , iii . Hemoglobin ≥8.0 gm/dL ( may receive RBC transfusion ) b . Adequate renal function define i. Creatinine clearance radioisotope GFR ≥70 mL/min/1.73 m2 ii . A serum creatinine base age/gender follow ( Maximum Serum Creatinine ( mg/dL ) ) : Males : 6 &lt; 10 years:1 ; 10 &lt; 13 year : 1.2 ; 13 &lt; 16 year : 1.5 ; &gt; 16 year 1.7 . Females : 6 &lt; 10 years:1 ; 10 &lt; 13 year 1.2 ; 13 &lt; 16 year : 1.4 ; &gt; 16 year : 1.4 . The threshold creatinine value derive Schwartz formula estimate GFR ( Schwartz et al . J. Peds , 106:522 , 1985 ) utilize child length stature data publish CDC . c. Adequate Liver Function Defined As : . Total bilirubin ( sum conjugated+unconjugated ) ≤1.5 time upper limit normal ( ULN ) age , ii . SGPT ( ALT ) &lt; 2.5 upper limit normal ULN ) . For purpose study , ULN SGPT 45 U/L iii . Serum albumin ≥2 g/dL d. Adequate cardiac function define : . Shortening fraction ejection fraction great LLN ( institutional norm ) , ii . Corrected QT interval ≤450 msec e. Normal Pancreatic function define : i. Serum amylase ≤1.5xULN ii . Serum lipase ≤1.5xULN . f. Blood pressure within upper limit normal define : . A blood pressure ( BP ) ≤ 95th percentile age , height , gender receive medication treatment hypertension . 7 . Informed Consent : All patient and/or parent legal guardian must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . 1 . Prior anthracycline treatment . Patients previously treat anthracyclines ( dose ) eligible . 2 . Prior Cardiac Radiation Patients previously treat radiation field include heart eligible . 3 . Pregnancy BreastFeeding Animal study indicate increase risk death pregnant female rat rabbit expose Sutent® . Cleft lip palate observe fetus expose utero sunitinib . There yet available information regard human fetal teratogenic toxicity . Pregnancy test must obtain girl poetmenarchal . Males female reproductive potential may participate unless agree use effective contraceptive method . 4 . Concomitant Medications 1 . Growth factor ( ) : Growth factor support platelet white cell number function must administer within past 14 day 2 . Investigational Drugs : Patients currently receive another investigational drug . 3 . Anticancer agent : Patients currently receive anticancer agent . 4 . The following CYP3A4 inducer prohibit 12 day start Sutent® study Sutent® : rifampin , rifabutin , carbamazepine , Phenobarbital , phenytoin , St. John 's wort , efavirenz , tipranavir . 5 . Antithrombotic antiplatelet agent : warfarin ( Coumadin ) , heparin , low molecular weight heparin , aspirin , and/or ibuprofen , NSAIDs . 6 . The following CYP3A4 inhibitor prohibit 7 day start sunitinib study sunitinib : azole antifungal ( itraconazole , ketoconazole ) ; clarithromycin , erythromycin , diltiazem , verapamil , HIV protease inhibitor ( indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) ; delavirdine . 5 . Infection : Patients uncontrolled infection . 6 . Pleuralbased tumor : Pediatric patient treat phase II trial imatinib high expect rate hemorrhagic pleural effusion . Sutent® inhibit two receptor tyrosine kinases imatinib , PDGFR cKIT . Patients tumor involve abut pleural surface exclude study . Patients pulmonary lesion monitor closely development hemorrhagic pleural effusion . 7 . Patient size : Due dose limitation , patient body surface area &lt; 0.5 m2 exclude study . 8 . Patients preexist thyroid abnormality ( hyperor hypothyroidism ) unstable thyroid function exclude study . For purpose study , unstable thyroid function define thyroid function abnormality require e change thyroid medication 6 month prior study entry . 9 . Patients history allergic reaction attribute Sutent® component Sutent® capsule . 10 . Prior use Sutent® : Patients previously receive sunitinib eligible study . 11 . Patients opinion investigator may able comply safety monitoring requirement study . 12 . Patient &lt; 5 year free another primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . 13 . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) 14 . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . 15 . Patient known brain metastasis . Nonspecific CNS change MRI/CT characteristic NF1 allow , know CNS malignancy . 16 . Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . 17 . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . 18 . Patient major surgery within 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NF1</keyword>
	<keyword>plexiform neurofibroma</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Sutent®</keyword>
</DOC>